leadf
logo-loader
RNS
viewHemoGenyx Pharmaceuticals

Hemogenyx Pharma Plc - Result of General Meeting

RNS Number : 8255K
Hemogenyx Pharmaceuticals PLC
06 January 2021
 

6 January 2021

 

Hemogenyx Pharmaceuticals plc 

("Hemogenyx Pharmaceuticals" or the "Company")

 

Result of General Meeting

 

 

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the General Meeting held earlier today, all resolutions were duly passed. The numbers of votes for each resolution are presented below.

 

General Meeting Voting Results

Ordinary Resolutions

Votes for

% of votes cast for

Votes Against

% of votes cast against

Total votes cast

Total votes cast as % of ISC (1)

Votes with-held (2)

1. To grant the Directors the authority to issue the Convertible Loan Notes

152,836,161

99.93%

110,000

0.07%

152,946,161

35.27%

10,000

2. To authorise the allotment of shares and the right to subscribe for or convert any security into shares

152,836,161

99.93%

110,000

0.07%

152,946,161

35.27%

10,000

Special Resolutions

Votes for

% of votes cast for

Votes against

% of votes cast against

Total votes cast

Total votes cast as % of ISC (1)

Votes with-held (2)

3. To disapply statutory pre-emption provisions

152,836,161

99.93%

110,000

0.07%

152,946,161

35.27%

10,000

 

(1)        The Company's issued share capital ("ISC") on 4 January 2021, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 433,636,255 ordinary shares.

(2)        A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

 

 

Enquiries:

 

Hemogenyx Pharmaceuticals plc

https://hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

headquarters@hemogenyx.com

Peter Redmond, Director

peter.redmond@hemogenyx.com





SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl







Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow



 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMEQLFBFFLEBBF

Quick facts: HemoGenyx Pharmaceuticals

Price: -

Market: LSE
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18

4 min read